A Retrospective Study Reveals the Relationship Between gp42-IgG Epitopes and EBV-associated NPC

Last updated: September 4, 2023
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Nasopharyngeal Cancer

Treatment

Epitope exploration

Clinical Study ID

NCT05949749
SYSKY-2023-631-01
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Epstein-barr virus (EBV) infection is a necessary factor of nasopharyngeal carcinoma (NPC). The incidence of NPC in endemic regions reaches 24.60/100,000 people, far higher than that of the worldwide average. However, no EBV prophylactic vaccines is clinically available so far, which is largely hampered by the difficulties in selecting optimal vaccine design target out of 13 glycoproteins on the surface of EBV. In this study, we utilized humanized gp42-IgG antibodies to explore the dominant epitopes of gp42, one of the functional EBV glycoproteins during virus entry, to facilitate prophylactic vaccine design.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Controls underwent physical examinations or primary NPC cases confirmed by pathologyor cytology.
  • If cases, at stage I-IVB diagnosed by radiology according to AJCC/UICC 8th.
  • If cases, Karnofsky score (KFS)≥70, estimated survival span>12 months.
  • If cases, no disordered of major organs is found; blood test, liver, and kidneyfunctions are basically normal.
  • If cases, at least one measurable lesion according to Response Evaluation Criteria inSolid Tumours (RECIST) 1.1.

Exclusion

Exclusion Criteria:

  • History of other malignant diseases.
  • History of severe systemic diseases or heart, lung, liver, or kidney disfunction.
  • History of severe neurological, metal, endocrine diseases.
  • History of HBV, HCV, HIV, TP, or TB infection.
  • If controls, physical examination reveals systemic diseases including malignantdiseases.
  • If cases, incomplete blood and pathological sample data.
  • If cases, not receiving primary treatment in this facility.
  • Other individuals investigators find not suitable for the trial.

Study Design

Total Participants: 1000
Treatment Group(s): 1
Primary Treatment: Epitope exploration
Phase:
Study Start date:
August 25, 2023
Estimated Completion Date:
September 30, 2024

Connect with a study center

  • Sun Yat-sen Memorial Hospital

    Guangzhou, Guangdong 510000
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.